Vernalis: Tuzistra XR Downgrade Prompts Strategic Rethink
Edison | Feb 28, 2018 07:02AM ET
Vernalis PLC ADR (OTC:VNLPY) has provided a trading and operational update to its guidance for Tuzistra XR prescriptions for financial year-end 2018. Despite dynamic management of commercial initiatives, Tuzistra XR prescription growth is not accelerating fast enough to meet Vernalis’s guidance of 105-115k prescriptions (given at the FY17 results). Following a disappointing uptake in the current cough cold season (~65% of the season is complete), Vernalis is downgrading guidance on prescription numbers and, in light of slow progress in the US cough and flu business, is seeking alternative strategies for the US business and the group. As such, we place our financial forecasts and valuation under review until we receive clarity on strategic next steps and the potential impact on cash burn, given a cash balance of £44m (unaudited at 31 January 2018).
Tuzistra XR is failing to accelerate prescription (Rx) growth to an adequate run rate to meet FY17-18 guidance of 105-115k prescriptions. While prescriptions have grown steadily (+74% for the first 33 weeks of 2017/18), with 65% of the cough cold season complete, a lack of acceleration over the last few months translates to a downgrade to below 105-115k. Coupled with a lack of any significant updates from partner Tris on the regulatory status of pipeline assets CCP-07 and CCP-08 (Complete Response Letters issued last year raised outstanding questions that must be resolved prior to NDA resubmission and an FDA approval decision) or achieving proof of concept for CCP-06, Vernalis is rethinking its US business strategy and a more detailed update will ensue in the coming weeks. Vernalis has signalled that these plans will reduce the cash burn of the business. We highlight that success of the US cough cold business has been dependent both on Tuzistra XR uptake, but additionally on launching follow-up compounds to maximise operational leverage in the US business.
To read the entire report Please click on the pdf File Below:
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.